Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.
Johnson & Johnson is one of the top healthcare companies in the world, with a market cap of nearly $400 billion. The company, however, faces an uncertain future because of its unsettled talc lawsuits.
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy
Advisers to the U.S. Food and Drug Administration on Friday unanimously voted in favor of allowing the use of Johnson & Johnson's cell therapy as an earlier treatment for a type of blood cancer.
The 3 Most Undervalued Healthcare Stocks to Buy in March 2024
Undervalued healthcare stocks are primed for a comeback this year, proving themselves as lucrative investments amidst a revitalized market. With a significant uptick in performance, the S&P 500 Hea...
2 High-Yield Dow Jones Dividend Stocks to Buy Now and Hold Forever
Stocks don't enter the Dow Jones Industrial Average index unless their underlying businesses are reliably profitable. Johnson & Johnson has raised its dividend payout 61 years in a row.
J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.
Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw Johnson & Johnson (JNJ) settling at $161.23, representing a +1.07% change from its previous close.
Latest J&J talc trial ends with hung jury
The latest trial over claims that Johnson & Johnson's talc products cause cancer ended in a mistrial on Tuesday, as a Florida state court jury said it could not agree on a verdict.
Johnson & Johnson (JNJ) Management presents at Cowen 44th Annual Health Care Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Hani Abouhalka - Company Group Chairman, Robotics and Digital, Johnson & J...
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
Will Johnson & Johnson Be a Trillion-Dollar Stock by 2030?
Johnson & Johnson has been leaning on acquisitions lately to strengthen its portfolio of products. The company expects to grow at an annual rate of around 5% or better until the end of the decade.
FDA approves J&J's combination therapy for a type of lung cancer
The U.S. health regulator on Friday approved Johnson & Johnson's therapy in combination with other chemotherapies for the first-line treatment of a type of lung cancer.
Want $1,000 in Ultra-Safe Annual Dividend Income? Invest $19,000 Into the Following 3 Time-Tested Dividend Kings.
Dividend stocks have handsomely outpaced the average annual return of non-payers over the past 50 years. Wall Street's Dividend Kings -- companies that have increased their payouts for at least 50 ...
Johnson & Johnson Stock Has 33% Upside, According to 1 Wall Street Analyst
Johnson & Johnson now has a slimmer business model than before. It may be launching a handful of products this year as well.
Johnson & Johnson (JNJ) Rises But Trails Market: What Investors Should Know
Johnson & Johnson (JNJ) concluded the recent trading session at $160.98, signifying a +0.12% move from its prior day's close.
Should You Pick Johnson & Johnson Stock At $160?
Johnson & Johnson (NYSE: JNJ) reported its Q4 results last month, with revenues and earnings marginally above the street estimates. The company reported revenue of $21.4 billion and adjusted earnin...
Related Companies